To include your compound in the COVID-19 Resource Center, submit it here.

Ameluz aminolevulinic acid: Phase III started

Biofrontera began an observer-blind, European Phase III trial to compare topical Ameluz plus daylight PDT

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE